10
Participants
Start Date
March 1, 2023
Primary Completion Date
April 30, 2024
Study Completion Date
June 30, 2024
variability-based lenvatinib regimen
Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
RECRUITING
Hadassah Medical Organization, Jerusalem
Hadassah Medical Organization
OTHER